| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/CID/CIQ072 |
| P698 | PubMed publication ID | 21148526 |
| P50 | author | Gerd Pluschke | Q28870485 |
| Jordi Landier | Q56356606 | ||
| Laurent Marsollier | Q89271865 | ||
| P2093 | author name string | Annick Chauty | |
| Ambroise Adeye | |||
| Marie-Françoise Ardant | |||
| Jane Cottin | |||
| Baohong Ji | |||
| Aimé Goundoté | |||
| Therese Ruf | |||
| Titilola Ladikpo | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Benin | Q962 |
| Mycobacterium ulcerans | Q141154 | ||
| P304 | page(s) | 94-96 | |
| P577 | publication date | 2011-01-01 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin | |
| P478 | volume | 52 |
| Q35702681 | A Field Study in Benin to Investigate the Role of Mosquitoes and Other Flying Insects in the Ecology of Mycobacterium ulcerans |
| Q35855507 | A Genomic Approach to Resolving Relapse versus Reinfection among Four Cases of Buruli Ulcer. |
| Q28538259 | Accelerated detection of mycolactone production and response to antibiotic treatment in a mouse model of Mycobacterium ulcerans disease |
| Q34075761 | Adequate wound care and use of bed nets as protective factors against Buruli Ulcer: results from a case control study in Cameroon |
| Q36291527 | Analysis of Mycobacterium ulcerans-specific T-cell cytokines for diagnosis of Buruli ulcer disease and as potential indicator for disease progression. |
| Q46241939 | Buruli Ulcer, a Prototype for Ecosystem-Related Infection, Caused by Mycobacterium ulcerans |
| Q59132198 | Buruli Ulcer: a Review of the Current Knowledge |
| Q90325400 | Buruli ulcer: cured by 8 weeks of oral antibiotics? |
| Q35689285 | Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model |
| Q36618316 | Clinical Features of Spontaneous Partial Healing During Mycobacterium ulcerans Infection |
| Q37544684 | Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. |
| Q34006790 | Clinical features and management of a severe paradoxical reaction associated with combined treatment of Buruli ulcer and HIV co-infection |
| Q37713494 | Comparison of two assays for molecular determination of rifampin resistance in clinical samples from patients with Buruli ulcer disease |
| Q42932818 | Compliance with antimicrobial therapy for buruli ulcer |
| Q34431496 | Corticosteroid use for paradoxical reactions during antibiotic treatment for Mycobacterium ulcerans |
| Q34500901 | Corticosteroid-induced immunosuppression ultimately does not compromise the efficacy of antibiotherapy in murine Mycobacterium ulcerans infection |
| Q35241003 | Development of a dry-reagent-based qPCR to facilitate the diagnosis of Mycobacterium ulcerans infection in endemic countries |
| Q24186073 | Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease) |
| Q57688861 | Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease) |
| Q51325790 | Economic inequality caused by feedbacks between poverty and the dynamics of a rare tropical disease: the case of Buruli ulcer in sub-Saharan Africa. |
| Q28552524 | Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease |
| Q35911339 | In vitro antibacterial activity and in vivo efficacy of hydrated clays on Mycobacterium ulcerans growth |
| Q34978950 | Incidence, clinical spectrum, diagnostic features, treatment and predictors of paradoxical reactions during antibiotic treatment of Mycobacterium ulcerans infections |
| Q40789030 | Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort |
| Q37457023 | Multifocal Buruli Ulcer Associated with Secondary Infection in HIV Positive Patient |
| Q34855365 | Mycobacterium ulcerans disease: experience with primary oral medical therapy in an Australian cohort |
| Q28543227 | Mycobacterium ulcerans treatment--can antibiotic duration be reduced in selected patients? |
| Q36900084 | Probable Buruli Ulcer Disease in Honduras |
| Q90325404 | Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial |
| Q34420330 | Screening of antifungal azole drugs and agrochemicals with an adapted alamarBlue-based assay demonstrates antibacterial activity of croconazole against Mycobacterium ulcerans |
| Q58785246 | Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer |
| Q36037938 | Spatial Distribution of Mycobacterium ulcerans in Buruli Ulcer Lesions: Implications for Laboratory Diagnosis |
| Q28552736 | Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice |
| Q34137837 | Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study |
| Q54244186 | Surgery for Buruli ulcer in the antibiotic era. |
| Q37539074 | Susceptibility Profiles of Mycobacterium ulcerans Isolates to Streptomycin and Rifampicin in Two Districts of the Eastern Region of Ghana |
| Q99633705 | Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses |
| Q35059761 | The urgent need for clinical, diagnostic, and operational research for management of Buruli ulcer in Africa |
| Q35625819 | Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife? |
| Q43932407 | Tropical medicine/tropical dermatology training in Tanzania and Ghana: Personal experience and selected case reports |
Search more.